ENTA - Enanta Pharmaceuticals, Inc.
| Previous Close | 78.84 |
| Open | 78.59 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 800 |
| Day's Range | 78.26 - 80.35 |
| 52 Week Range | 44.52 - 127.77 |
| Volume | 206,643 |
| Avg. Volume | 274,457 |
| Market Cap | 1.53B |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | 19.98 |
| EPS (TTM) | 3.95 |
| Earnings Date | Nov 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 104.00 |
- Simply Wall St.•10 days ago
How Good Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA), When It Comes To ROE?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
- ACCESSWIRE•17 days ago
Liver Cancers Rising - Stocks to Watch
HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people ...
- GlobeNewswire•27 days ago
Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that two abstracts have been accepted for presentation at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, October 31 through November 4, 2018. EDP-938, Enanta’s lead non-fusion inhibitor, is being developed for the treatment of RSV infection.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q3 2018 Enanta Pharmaceuticals Inc Earnings Call
- Business Wire•2 months ago
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R.
- InvestorPlace•2 months ago
Why Enanta Stock Is Still a Strong Buy With Huge Upside
Enanta Pharmaceuticals (NASDAQ:ENTA) has been in the news recently. Before I get around to what’s been happening with ENTA stock recently, it may help to get a broader understanding of how the company operates and what exactly it does. What used to be a fairly typical model, where you discover a drug, run it through the various drug trials, build a marketing plan and sell the drug, has now become much more focused.
- Zacks•2 months ago
Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 1.04% and 1.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Watertown, Massachusetts-based company said it had profit of 97 cents. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
Webcast and Conference Call today at 4:30 p.m. ET
- Zacks•3 months ago
Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Business Wire•3 months ago
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018
Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2018, after the U.S. markets close on August 7, 2018. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers.
- Zacks•4 months ago
Achieve Life Sciences' Shares Rise on Positive Clinical Data
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
- InvestorPlace•4 months ago
2 Stable and 2 Speculative Biotech Stocks to Buy
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
- Business Wire•4 months ago
Enanta Pharmaceuticals Recognizes the 1st International NASH Day
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, is proud to support the 1st International NASH Day taking place today. This is a ground-breaking event organized by the NASH Education Program and its benefactors and supporters around the world. NASH is expected to become the #1 cause of liver transplant by 2020 in the United States, and its prevalence is projected to increase globally in association with obesity and type 2-diabetes.
- ACCESSWIRE•5 months ago
Today's Research Reports on Stocks to Watch: Enanta Pharmaceuticals and Vascular Biogenics
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
- Zacks•5 months ago
Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
- Business Wire•5 months ago
Enanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, President and Chief Executive Officer will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
- Zacks•5 months ago
Bayer's Generic Competition, Pipeline Setback Issues Remain
Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).
- Zacks•5 months ago
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y
Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.
- Market Realist•5 months ago
Analysing NVR, DPZ, ENTA And QLYS Stocks
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
- Market Realist•5 months ago
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
- Zacks•5 months ago
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.
